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Abstract
Background: Chungsim-Yeunja-Tang (CYT) has been used as a medicine for cerebral infarction (CI) patients in
Korea. The objective of this study was to determine precisely the effect of CYT on CI patients using peripheral
blood mononuclear cells (PBMCs).
Methods: For a clinical study, 47 CI patients were identified who had taken CYT (0.01 g/kg) 3 times a day after
meals for 2 weeks by oral administration. For ex vivo experiments, peripheral blood mononuclear cells (PBMCs)
were isolated from CI patients. We analyzed the effect of CYT and its main components on lipopolysaccharide
(LPS)-induced cytokine production and mechanism on PBMCs of CI patients by using ELISA, western blot analysis,
transcription factor enzyme-linked immunoassay, and caspase assay.
Results: Clinical signs of CI significantly disappeared about 2 weeks after oral administration of CYT to CI patients
(P < 0.05). CYT and quercetin, an active compound of CYT, significantly inhibited LPS-induced interleukin (IL)-1b, IL-
6, and tumor necrosis factor (TNF)-a production and expression in PBMCs. CYT and quercetin also inhibited LPS-
induced nuclear translocation and DNA binding activities of nuclear factor-B and degradation of IBa. In addition,
CYT and quercetin inhibited LPS-induced IL-32 expression and caspase-1 activation.
Conclusion: These results suggest a mechanism that might explain the beneficial effect of CYT in treating CI
patients. Taken together, our findings indicate that inhibition of IL-32 expression and caspase-1 activation may be a
novel biomarker and potential therapeutic target in CI.
Background
Chungsim-Yeunja-Tang (CYT), a traditional Korean
medicine, has long been prescribed as a treatment for
cerebral infarction (CI) to increase cerebral blood flow
and to recover injured brain cells. We have previously
reported that CYT regulates the serum level of cytokines
in patients with acute CI [1]. However, the effects of
CYT on the regulation of inflammatory cytokine pro-
duction are still not completely understood. The use of
herbal therapies or alternative medicines is becoming an
increasingly attractive approach for the treatment of var-
ious inflammatory disorders.
Inflammatory processes are orchestrated by inflamma-
tory cells through a complex set of chemical signals and
c a na r i s ei na n yt i s s u ei nr e s p o n s et ot r a u m a t i c ,i n f e c -
tious, post-ischemic, toxic, allergic, or auto-immune
injury [2]. In chronic inflammatory diseases, the injury
persists and leads to tissue damage [2]. During inflam-
mation, the inflammatory region is infiltrated with
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mediators including inflammatory cytokines [3]. The
expression of inflammatory cytokines is dependent on
activation of a transcription factor, nuclear factor (NF)-
 B. Most commonly, NF-B dimers are composed of
Rel A (p65) and NFKB1 (p50) or NFKB2 (p52) subunits
[4,5]. NF-B binds to a specific consensus DNA element
present in the promoter region of target genes and initi-
ates transcription of tumor necrosis factor (TNF)-a and
interleukin (IL)-6 [6,7]. NF-B normally resides in the
cytoplasm, where it is retained by association with an
IBp r o t e i n( a,b,o rg), an endogenous inhibitor [5].
When activated, it translocates to the nucleus, binds to
DNA, and activates genes. This activation involves the
phosphorylation, ubiquitination, and degradation of IB,
leading to the nuclear migration of NF-B [8,9]. NF-B
activation via receptor interacting protein-2 has been
found to involve caspase-1 [10]. In this case, NF-B
activation by lipopolysaccharide (LPS) is attenuated in
caspase-1-deficient macrophages and is inhibited by a
catalytically inactive form of caspase-1 [10].
IL-32, originally named NK cell transcript 4 (NK4), is
produced mainly by mitogen-activated lymphocytes,
interferon-g-activated epithelial cells, IL-12-, IL-18-, and
IL-32-activated NK cells; and IL-18 gene-transfected
cells [11]. Human IL-32 has six spice variants, IL-32 a,
IL-32b,I L - 3 2 g,I L - 3 2 δ,I L - 3 2 ζ,a n dI L - 3 2 ε [12,13].
Recombinant human IL-32g, the most recently described
inflammatory cytokine, stimulates production of IL-1b,
TNF-a, and macrophage inflammatory protein-2 [14].
IL-32 stimulates the secretion of IL-1b,I L - 6 ,I L - 8 ,a n d
TNF-a by activating NF-B and p38 mitogen-activated
protein kinase (MAPK) [12]. In addition, maturation of
IL-1b through a caspase-1-dependent mechanism is also
a property of IL-32 [14]. IL-32 production is dependent
on a proinflammatory pathway involving active IL-18
induced by a caspase-1-dependt pathway [15]. These
proinflammatory effects of IL-32 suggest an important
role for IL-32 in inflammation.
This paper evaluates the effects of CYT and its main
components on LPS-induced cytokine production and
expression in peripheral blood mononuclear cells
(PBMCs) of CI patients. In order to determine possible
mechanisms of the inhibitory actions of CYT, we also
investigated its effect on NF-B and caspase-1 activity.
Methods
Materials
Ficoll-Hypaque, LPS, avidin-peroxidase, 3-[4, 5-
Dimethylthiazole-2-yl]-2, 5,-diphenyl-tetrazolium bromi-
deand (MTT), quercetin, and 2’-azino-bis (3-ethylben-
zithiazoline-6-sulfonic acid) tablet substrates (ABTS)
were purchased from Sigma (St. Louis, MO, USA).
RPMI 1640, ampicillin, streptomycin and fetal bovine
serum (FBS) were purchased from Gibco BRL (Grand
Island, NY, USA). Anti-human IL-1b,T N F - a,a n dI L -
32, biotinylated anti-human IL-1b and TNF-a,r e c o m b i -
nant (r) human IL-1b and TNF-a, and a caspase-1 assay
kit were purchased from R&D Systems (Minneapolis,
MN, USA). Anti-human IL-6, biotinylated anti-human
IL-6, and rhuman IL-6 were purchased from Pharmin-
gen (San Diego, CA, USA). Recombinant IL-32 was pur-
chased from YbdYbiotech (Seoul, Korea)
Subjects
The subjects of this retrospective study were 47 CI
patients (diagnosed by magnetic resonance imager) who
had been treated with CYT in Kyung Hee Oriental
Medical Center. They were hospitalized within one
week of onset, treated for longer than one week, and
admitted between March 1
st, 1999 and February 28
th,
2001. The 47 CI patients had taken CYT (0.01 g/kg) 3
times a day after meals for 2 weeks by oral administra-
tion. Thirteen volunteers also participated in PBMC iso-
lation. Blood samples of CI patients were obtained from
the Department of Neurology College of Medicine and
Department of Sasang Constitutional Medicine, College
of Oriental Medicine, Wonkwang University. All
patients had basic tests (blood and urine tests, chest X-
ray, electrocardiogram) and treatment for ischemic
stroke. Informed consent was obtained from all subjects
before performing these studies.
PBMC isolation and culture
PBMCs from heparinized venous blood were isolated
with Ficoll gradient centrifugation, washed three times
in a phosphate-buffered saline (PBS) solution and
resuspended in RPMI 1640 medium (Gibco) supple-
mented with 2 mM L-glutamine, 100 U/ml penicillin
G, 100 μg/ml streptomycin, and 10% FBS inactivated
for 30 min at 56°C. The PBMCs were adjusted to a
concentration of 2 × 10
6 cells/ml in a 30 ml falcon
tube, and 100 μl aliquots of cell suspension were
placed in a four-well cell culture plate. The PBMCs
were cultured for 24 h in 95% humidified air contain-
ing 5% CO2 (37°C). To determine whether CYT can
modulate LPS-induced IL-1b,I L - 6 ,a n dT N F - a pro-
duction on PBMCs, the cells were pretreated with var-
ious concentrations of CYT (0.01, 0.1, and 1 mg/ml) or
quercetin (0.01, 0.1, and 1 mM) for 2 h prior to LPS
stimulation for 24 h, and the supernatants were col-
lected by centrifugation and stored at -20°C.
Preparation of CYT
The ingredients of 53.3 g of CYT included 8 g of
Nelumbo nucifera GAERTN, 4 g of Ophiopogon japoni-
cus KER-GAWL, 8 g of Dioscoreae japonica THUNB, 4
go fAcorus gramineus SOLAND, 4 g of Scutellaria
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of Biota orientalis ENDL, 4 g of Euphoria longan
STEUD, 4 g of Asparagus cochinchinensis MERR, 4 g of
Raphanus sativus L, 4 g of Polygala tenuifolia WILLD,
and 1.3 g of Chrysanthemum morifolium RAMAT. An
extract of CYT was prepared by decocting the dried
mixture of herbs with boiling distilled water (100 g/l).
The decoction was filtered, lyophilized, and kept at 4°C.
The yield of powdered extraction is commonly about
7% (w/w). The CYT aqueous extract powder was dis-
solved in sterile saline (100 mg/ml) and then filtered
using 0.22 μm syringe filter. 100 mg/ml CYT was
diluted with saline, and we used final concentrations of
0.01, 0.1, and 1 mg/ml of CYT for the experiments.
When the CYT extract was added to medium, it did not
precipitate. Quercetin is a component of Nelumbo nuci-
fera GAERTN (approximately 0.36-2.26%) [16], Biota
orientalis ENDL (approximately 1.76%) [17], Raphanus
sativus L (approximately 0.79%) [18], and Chrysanthe-
mum morifolium RAMAT (approximately 0.05%) [19].
The dosage of quercetin that is found in CYT (1 mg/
ml) was calculated to be about 0.02 mM. The plant
materials were obtained from Oriental Medicine Hospi-
tal, Wonkwang University and identified by J.C. Joo, of
the College of Oriental Medicine, Wonkwang University.
The voucher specimens (voucher No. 20020427) were
deposited in the herbarium in the College of Oriental
Medicine at Kyung Hee University.
MTT assay
The MTT colorimetric assay of cell survival was per-
formed using the method of Ben Trivedi et al., [20] with
minor modifications. Cell aliquots (2 × 10
5) were seeded
in microplate wells and incubated with 20 μlo faM T T
solution (5 mg/ml) for 4 h at 37°C under 5% CO2 and
95% air. Consecutively, 250 μlo fd i m e t h y ls u l f o x i d e
(DMSO) was added to extract the MTT formazan and
an automatic microplate reader measured the absor-
bance of each well at 540 nm.
ELISA of IL-1b, IL-6, and TNF-a
Cytokine production was measured by a modified sand-
wich ELISA method, as described previously [21]. ELISA
for IL-1b, IL-6, and TNF-a was carried out in duplicate
in 96-well ELISA plates (Nunc) coated with each of 100
μl aliquots of mouse anti-human IL-1b, IL-6, and TNF-
a monoclonal antibodies at 1.0 μg/ml in PBS at pH 7.4
and was incubated overnight at 4°C. The plates were
washed in PBS containing 0.05% Tween-20 (PBST) and
blocked with PBS containing 1% BSA, 5% sucrose and
0.05% NaN3 for 1 h. After additional washes, sample or
IL-1b, IL-6, and TNF-a standards were added and incu-
bated at 37°C for 2 h. After 2 h incubation at 37°C, the
wells were washed and then each of 0.2 μg/ml of
biotinylated anti-human IL-1b,I L - 6 ,a n dT N F - a were
added and again incubated at 37°C for 2 h. After wash-
ing the wells, avidin-peroxidase was added and plates
were incubated for 45 min at 37°C. Wells were again
washed and ABTS substrate (Sigma) was added. Color
development was measured at 405 nm using an auto-
mated microplate ELISA reader. A standard curve was
run on each assay plate using recombinant human IL-
1b,I L - 6 ,a n dT N F - a in serial dilutions. The inhibition
percentage of cytokine production was calculated using
the following equation:
% { () () } / () Inhibition c b s b c b =− − −× − 100
where c is LPS-induced cytokine production without
CYT and s is LPS+CYT or quercetin-induced cytokine
production (b, unstimulated cells).
ELSIA of IL-32
IL-32 production was measured by direct ELISA
method. ELISA for IL-32 was carried out in duplicate in
96-well ELISA plates coated with each of 100 μl aliquots
of sample or recombinant IL-32 and was incubated
overnight at 4°C. The plates were washed in PBST and
blocked with PBS containing 1% BSA, 5% sucrose and
0.05% NaN3 for 1 h. After a 2 h incubation at 37°C, the
wells were washed and then 0.2 μg/ml of anti-human
IL-32 was added and the cells again incubated at 37°C
for 2 h. After washing the wells, goat horse radish per-
oxidase conjugated antibody was added and plates were
incubated for 45 min at 37°C. Wells were again washed
and ABTS substrate (Sigma) was added. Color develop-
ment was measured at 405 nm using an automated
microplate ELISA reader. A standard curve was run on
each assay plate using recombinant human IL-32 in
serial dilutions.
Reverse-transcriptase polymerase chain reaction (RT-PCR)
analysis
Total RNA was isolated from PBMCs according to the
manufacturer’s specifications using the Easy-BLUE™RNA
extraction kit (iNtRON Biotech, Taejeon, Republic of
Korea). The concentration of total RNA in the final
elutes was determined by spectrophotometry. Total
RNA (1 μg) was heated at 65°C for 10 min and then
chilled on ice. Each sample was reverse-transcribed to
cDNA for 90 min at 37°C using a cDNA synthesis kit
(Amersham Pharmacia Biotech, Piscataway, NJ, USA).
The polymerase chain reaction (PCR) was performed
with the following primers for human (h) IL-1b (5 CCG
GAT CCA TGG CAC CTG TAC GAT CA 3; 5 GGG
GTA CCT TAG GAA GAC ACA AAT TG 3), IL-6
(5 GAT GGA TGC TTC CAA TCT GGA T 3; 5 AGT
TCT CCA TAG AGA ACA ACA TA 3), TNF-a
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C A CC A GC T GG T TA T CT C TC A GC T C3 ) ,I L - 3 2 g
(5 GTA ATG CTC CTC CCT ACT TC 3; 5 GCA AAG
GTG GTG TCA GTA TC 3), and GAPDH (5 CAA
AAG GGT CAT CAT CTC TG 3; 5 CCT GCT TCA
CCA CCT TCT TG 3) were used to verify that equal
amounts of RNA were used for reverse transcription
and PCR amplification under different experimental
conditions. The annealing temperature was 50°C for IL-
1b, 56°C for IL-6, 60°C for TNF-a,5 9 ° Cf o rI L - 3 2 g,a n d
62°C for GAPDH, respectively. Products were electro-
phoresed on a 1.5% agarose gel and visualized by stain-
ing with ethidium bromide.
Nuclear protein extraction
Crude nuclear extract was isolated from cells. After cell
activation for the times indicated, cells were washed in
1 ml of ice-cold PBS, centrifuged at 1000 × g for 5 min-
utes, resuspended in 400 μl of ice-cold hypotonic buffer
(10 mM HEPES/KOH, 2 mM MgCl2, 0.1 mM EDTA, 10
mM KCl, 1 mM DTT, O.5 mM PMSF, pH 7.9), left on
ice for 10 minutes, vortexed, and centrifuged at 15,000
× g for 30 s. Pelleted nuclei were gently resuspended in
50 μl of ice-cold saline buffer (50 mM HEPES/KOH, 50
mM KCl, 300 mM NaCl, 0.1 mM EDTA, 10% glycerol,
1 mM DTT, 0.5 mM PMSF, pH 7.9), left on ice for 20
min, vortexed, and centrifuged at 15,000 × g for 5 min
at 4°C. Aliquots of the supernatant, which contained
nuclear proteins, were frozen in liquid nitrogen and
stored at -70°C. Protein was determined using a Bicinch-
oninic acid protein assay method (Sigma, St. Louis, MO,
USA).
Western blot analysis
Cell extracts were prepared by detergent lysis procedure.
Cells (2 × 10
6 cells) were scraped, washed once with
PBS, and resuspended in lysis buffer. Samples were vor-
texed for lysis for a few seconds every 15 min at 4°C for
1 h and centrifuged at 15,000 × g for 5 min at 4°C.
Supernatants were assayed. Samples were heated at 95°C
for 5 min, and briefly cooled on ice. Following the cen-
trifugation at 15,000 × g for 5 min, 50 μg aliquots were
resolved by 10% SDS-PAGE. Resolved proteins were
electrotransferred overnight to nitrocellulose membranes
in 25 mM Tris, pH 8.5, 200 mM glycerin, and 20%
methanol at 25 V. Blots were blocked for at least 2 h
with 1 × PBST containing 5% nonfat dry milk. Protein
levels were analyzed essentially according to the manu-
facturer’s instructions.
Transcription factor enzyme-linked immunoassay (TF-EIA)
Avidin peroxidase was coated on a 96-well ELISA plate.
T h ec o a t e dp l a t ew a sw a s h e dw i t hP B S Ta n dt h e n
blocked with a 3% skim milk solution. The coated plate
was incubated with 1 μg/ml of 5’-biotinylated 21 single
strand DNA oligonucleotide sequence for 1 h at room
temperature. This sequence contains the previously
described NF-B binding motif. The sequences used
here were: 5 AGT TGA GGG GAC TTT CCC AGG 3.
A DNA-binding reaction was carried out in a total
volume 100 μlc o n t a i n i n g1 0μg nuclear protein extract
in a buffer containing 10 mM HEPES (pH 7.9), 50 mM
NaCl, 5% glycerol, 1 mM EDTA, and 1 mM DTT, for 1
h at room temperature and then washed. NF-B antibo-
dies were then added at a 1:500 concentration in PBS
containing 3% BSA for 1 h, followed by the addition of
the corresponding alkaline phosphatase (AP)-coupled
secondary antibody. Between each addition, the wells
were extensively washed in PBST. AP activity was then
detected by the addition of p-nitrophenyl phosphate
(PNPP) solution (Sigma). After a 10-min incubation per-
iod, the reaction was arrested by the addition of 0.5 M
H2SO4, Color intensity was detected at 405 nm using
ELISA reader. AP activity was normalized to control
values (unstimulated cells).
Statistical analysis
Statistical differences between the groups were esti-
mated using an ANOVA with a Tukey post hoc test and
Mann-Whitney U-test. The results were considered sig-
nificant at a value of P < 0.05.
Results
Effect of CYT on CI patients
Subjects included in this study were 47 patients. Table 1
shows the general characteristics of the study group. We
compared the scores of NIH stroke scale (NIHSS),
Table 1 Baseline characteristics of the study subjects
Characteristic CYT Medication
(N = 47)
Female sex, n (%) 30 (64)
Age, year (SD) 62.9 (13.9)
Time since stroke, day (SD) 2.1 (1.6)
Admitting day (SD) 24.7 (18.4)
Medical history
Hypertension, n (%) 26 (55)
Diabetes Mellitus, n (%) 10 (21)
Social history
Smoking, n(%) 14 (30)
Alcohol, n(%) 16 (34)
Motor grade (upper limb) (SD) 3.8 (1.5)
Motor grade (lower limb) (SD) 3.8 (1.4)
NIH Stroke Scale (SD) 3.6 (4.1)
Modified Barthel Index (SD) 72.4 (32.9)
CYT, Chungsim-Yeunja-Tang; SD, standard deviation; FBS, fasting blood sugar;
LDL-c, low density lipoprotein cholesterol. CYT was administrated orally for 2
weeks.
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limb), and motor grade (lower limb) between admission
and discharge date. Discharge date scores (N = 47) of
MBI, motor grade (upper limb), and motor grade (upper
limb) were significantly higher than those from the
admission date (P = 0.040, 0.030, and 0.011, respec-
tively), but there was no significant difference in NIHSS
scores (P = 0.086) (Table 2).
Effect of CYT on LPS-induced cytokine production by
PBMCs
To determine whether CYT can modulate LPS-induced
IL-1b, IL-6, and TNF-a production in PBMCs, the cells
were pretreated with various concentrations of CYT
(0.01, 0.1, and 1 mg/ml) for 2 h prior to LPS stimulation
for 24 h. Culture supernatants were assayed for IL-1b,
IL-6, and TNF-a protein levels by ELISA method. LPS
(10 ng/ml) increased cytokine production in the
PBMCs. However, in LPS-stimulated cells, IL-1b,I L - 6 ,
and TNF-a production was decreased by treatment of
CYT (about 183 ± 11.4% for IL-1b, 82.3 ± 12% for IL-6,
and 71.4 ± 4.4% for TNF-a at 1 mg/ml, P <0 . 0 5 ) .C Y T
inhibited LPS-induced IL-1b,I L - 6 ,a n dT N F - a produc-
tion in a dose-dependent manner (Figure 1). Cell cyto-
toxicity of CYT was not observed (data not shown).
Effect of components of CYT on LPS-induced cytokine
production on PBMCs
To determine whether quercetin, hyperoside (a compo-
nent of Nelumbo nucifera GAERTN), or baicalein (a
component of Scutellaria baicalensis GEORGI) can
modulate LPS-induced IL-1b, IL-6, and TNF-a produc-
tion on PBMCs, the cells were pretreated with various
concentrations of quercetin (0.01, 0.1, and 1 mM),
hyperoside (0.01, 0.1, and 1 mM), or baicalein (0.01, 0.1,
and 1 mM) for 2 h prior to LPS stimulation for 24 h.
Culture supernatants were assayed for IL-1b,I L - 6 ,a n d
TNF-a protein levels by ELISA method. Quercetin
inhibited LPS-induced IL-1b,I L - 6 ,a n dT N F - a produc-
tion (about 103.7% for IL-1b, 100.5% for IL-6, and
102.8% for TNF-a at 0.1 mM, P < 0.01, Figure 2). The
estimated IC50 values of IL-1b,I L - 6 ,a n dT N F - a pro-
duction were about 0.009, 0.046, and 0.007 mM, respec-
tively. Cell cytotoxicity of quercetin at concentrations of
0.01 and 0.1 mM was not observed (data not shown)
but 1 mM quercetin does show cell cytotoxicity.
Hyperoside and baicalein did not affect LPS-induced
inflammatory cytokine production (data not shown).
Effects of CYT and quercetin on LPS-induced cytokine
mRNA expression in PBMCs
To determine whether CYT can modulate LPS-induced
cytokine expression, cells were pretreated with CYT or
quercetin for 2 h prior to LPS stimulation. We per-
formed the RT-PCR analysis for IL-1b,I L - 6 ,a n dT N F -
aat 8 h. mRNA expression was up-regulated by LPS but
the up-regulated IL-1b, IL-6, and TNF-a mRNA expres-
sion was decreased by treatment with CYT (1 mg/ml)
or quercetin (0.1 mM) (Figure 3).
Effects of CYT and quercetin on LPS-induced NF-B
activation
The expression of inflammatory cytokines is regulated
by the transcription factor, nuclear factor (NF)-  B/Rel
[6,7]. Expression levels of NF-B/Rel A (p65) in the
nucleus and cytoplasm of PBMCs was examined using
western blot analysis. In LPS-stimulated cells, the
expression level of NF-B (p65) declined in the cyto-
plasm and concurrently increased in the nucleus. How-
ever, the expression level of NF-B (p65) in the nucleus
decreased by treatment with CYT or quercetin (Figure
4A). We also investigated the effect of CYT on LPS-
induced NF-B transcription complex. To perform these
studies, we used an NF-B TF-EIA method. This assay
has the advantage of being 10 times more sensitive than
an electrophoretic mobility shift assay, and it allows
greater flexibility in the experimental step. As shown in
Figure 4B, LPS increased DNA-binding activity for NF-
B, but this increased binding activity was decreased by
treatment with CYT (1 mg/ml) or quercetin (0.1 mM).
Activation of NF-B required phosphorylation and pro-
teolytic degradation of the inhibitory protein IBa.T o
determine whether the inhibitory action of CYT was
due to the effect on IBa degradation, cytoplasmic
levels of IBa protein were examined after LPS-stimula-
tion using a western blot analysis. CYT or quercetin
also decreased degradation of IBa (Figure 4C). Neither
b-actin nor histone expression levels in the nucleus or
cytosol extracts changed with either treatment.
Effects of CYT and quercetin on LPS-induced IL-32
expression in PBMCs
IL-32 stimulates the secretion of inflammatory cytokines
by activating NF-B [12]. To determine whether CYT
or quercetin can modulate LPS-induced IL-32
Table 2 Changes of NIHSS, MBI, and motor grade of CYT
medication group
baseline after 2weeks
Items Mean Mean P*
NIHSS 3.6 ± 4.1 2.0 ± 2.3 0.086
MBI 72.4 ± 32.9 86.8 ± 18.7 0.040
Motor grade
(upper limb)
3.8 ± 1.5 4.2 ± 1.0 0.030
Motor grade
(lower limb)
3.8 ± 1.4 4.3 ± 0.8 0.011
CYT, Chungsim-Yeunja-Tang; NIHSS, NIH stroke scale; MBI, Modified Barthel
Index. N = 47.
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various concentrations of CYT (0.01, 0.1, and 1 mg/ml),
quercetin (0.01 and 0.1 mM) or caspase-1 inhibitor (10
μM) for 2 h prior to LPS stimulation for 24 h. Culture
supernatants were assayed for IL-32 protein levels by
the ELISA method. CYT, quercetin, and caspase-1 inhi-
bitor all significantly inhibited LPS-induced IL-32 pro-
duction (Figure 5A). To determine whether CYT or
quercetin can modulate LPS-induced IL-32 mRNA
expression, cells were pretreated with CYT or quercetin
for 2 h prior to LPS stimulation. As shown in Figure 5B,
mRNA expression was up-regulated by LPS, but the up-
regulation decreased with CYT (1 mg/ml) and quercetin
(0.1 mM) treatments.
Effects of CYT and quercetin on LPS-induced caspase-1
activation
Caspase-1 is activated in a variety of inflammatory
responses; caspase-1 was activated by treatment with
LPS [15]. We investigated the inflammatory pathway
involving caspase-1. To determine if CYT or quercetin
inhibits caspase-1 activation induced by LPS, cells were
exposed to LPS in the presence or absence of CYT (1
mg/ml) or quercetin (0.1 mM). Extracts prepared from
PBMCs exposed to LPS contained strong caspase-1
activity compared with unstimulated cells. As shown in
Figure 6A, increased caspase-1 activity was significantly
inhibited by treatment with CYT or quercetin (P <
0.05). Caspase-1 is present in cells as an inactive zymo-
gen and is activated by LPS treatment. The activation of
caspase-1 plays an important role in NF-Ba c t i v a t i o n
and IL-32 production [10,15]. Caspase-1 precursor pro-
tein was evaluated by western blot analysis. Western
blot analysis indicates that LPS treatment induced
degradation of caspase-1 precursor, which was inhibited
by treatment CYT or quercetin (Figure 6B).
Discussion
Herbal remedies and botanicals are widely used by
humans for both preventative and curative purposes.
Figure 1 Effect of CYT on LPS-induced cytokine production. Peripheral blood mononuclear cells (PBMCs) (2 × 10
5) were treated with various
concentrations of Chungsim-Yeunja-Tang (CYT) for 2 h and then stimulated with LPS (10 ng/ml) for 24 h. Cytokine concentrations were
measured in cell supernatants using the ELISA method. Data shown are the inhibition rate ± S.D. for 10 donors, measured in duplicate. *P <
0.05, significantly different from the unstimulated cells. **P < 0.05 compared to LPS alone.
Figure 2 Effect of quercetin on LPS-induced cytokine production. PBMCs (2 × 10
5) were treated with various concentrations of quercetin for
2 h and then stimulated with LPS (10 ng/ml) for 24 h. Cytokine concentrations were measured in cell supernatants using the ELISA method.
Data shown are the inhibition rate ± S.D. for 10 donors, measured in duplicate. *P < 0.05, significantly different from the unstimulated cells. **P
< 0.05 compared to LPS alone.
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any) side effects, and display low cytotoxicity, and so the
search for the use of natural products in traditional
medicine is currently attracting intense interest. In pre-
vious studies, we have investigated the effects of various
traditional medicines (Yulda-Hanso-Tang, Gigukji-
whangwhan-gami, Seogak Jihwag-Tang, Jeo Dang-Tang,
and Yangkyuk-Sanhwa-Tang) in patients with CI. We
reported that Th2 cytokine (IL-1b, IL-4, and IL-6) levels
are higher than Th1 cytokine (IL-2 and IFN-g) levels in
patients during the acute stage of CI and that traditional
medicines regulate the Th1/Th2 cytokine unbalance in
patients with CI [22]. As part of our continuing search
for biologically active anti-inflammatory agents from
oriental medicines, we investigated CYT. As described
above, CYT consists of 12 different herbs. Our previous
studies showed that an aqueous extract of Asparagus
cochinchinensis inhibits the secretion of TNF-a from
primary cultures of mouse astrocytes [23] and Hep G2
cells [24]. It has been reported that a fructan, Opaw-2,
isolated from Ophiopogon japonicus, stimulates prolif-
eration of cultured lymphocytes [25]. Extracts from
Nelumbo Nucifera suppress cell cycle progression, cyto-
kine gene expression, cell proliferation, and inflamma-
tory reactions [26,27]. Zhang et al. [28] reported that an
Figure 3 Effects of CYT and quercetin on LPS-induced cytokine
mRNA expression. PBMCs (2 × 10
6) were treated with CYT (1 mg/
ml) and quercetin (0.1 mM) for 2 h and then stimulated with LPS
(10 ng/ml) for 8 h. Messenger RNA was measured using the RT-PCR
method. Results are representative of three independent
experiments (A). Levels of mRNA were analyzed with densitometry
(B). Quer, quercetin. Figure 4 Effects of CYT and quercetin on LPS-induced NF-B
activation and IB degradation. PBMCs (2 × 10
6) were treated
with CYT (1 mg/ml) and quercetin (0.1 mM) for 2 h and then
stimulated with LPS (10 ng/ml) for 6 h. Nuclear and cytoplasmic
protein was prepared and analyzed for NF-B and IBa by western
blotting as described in the experimental procedures (A and C).
Nuclear protein was incubated in a 96-well plate coated with an
oligonucleotide containing the NF-B binding site. Presence of NF-
B transcription complex was evaluated with an NF-B antibody.
Results are expressed as the fold increases of absorbance at 405 nm
over control conditions (B). Results are representative of three
independent experiments. *P < 0.05, significantly different from the
unstimulated cells. **P < 0.05 compared to LPS alone. NE, nuclear
extract; CE, cytosol extract;Quer, quercetin.
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Page 7 of 11aqueous extract of Scutellaria baicalensis has a protec-
tive effect against acrolein-induced oxidative stress in
cultured human umbilical vein endothelial cells. Some
studies have suggested that wogonin, isolated from Scu-
tellariae Radix, has an anti-inflammatory effect [29] and
triterpenes, isolated from Chrysanthemi Flos,s h o wa n t i -
inflammatory activity against 12-O-tetradecanoylphor-
bol-13-acetate-induced inflammation in mice [30]. In
one study, quercetin downregulated LPS-induced TNF-
a and nitric oxide production [31]. In this study, CYT
and quercetin inhibited LPS-induced IL-1b,I L - 6 ,a n d
TNF-a production in PBMCs. CYT and quercetin also
increased IB by preventing its degradation. The
increased IB inhibited the translocation of NF-B/Rel
A to the nucleus and the DNA binding activity of NF-
B. CYT and quercetin also inhibited IL-32 production
and caspase-1 activation.
Cells activated by LPS produce cytokines that include
interferons, IL-1, IL-6, IL-8, TNF-a, platelet activating
factors, and procoagulant tissue factors [32]. The host
response to LPS involves multiple inflammatory effector
mechanisms, including cytokines [33]. IL-1 is an
Figure 5 Effects of CYT and quercetin on LPS-induced IL-32
production. PBMCs (2 × 10
5) were treated with CYT, quercetin, or
caspase-1 inhibitor (10 μM) for 2 h and then stimulated with LPS
(10 ng/ml) for 24 h. Cytokine concentrations were measured in cell
supernatants using the ELISA method (A). PBMCs (2 × 10
6) were
treated with CYT (1 mg/ml) or quercetin (0.1 mM) for 2 h and then
stimulated with LPS (10 ng/ml) for 8 h. Messenger RNA was
measured using RT-PCR method. Results are representative of three
independent experiments and band intensities correspond to levels
of IL-32/GAPDH rate (B).*P < 0.05, significantly different from the
unstimulated cells. **P < 0.05 compared to LPS alone. Quer,
quercetin.
Figure 6 Effects of CYT and quercetin on LPS-induced caspase-
1 activation. PBMCs (2 × 10
6/well) were treated with CYT (1 mg/
ml) or quercetin (0.1 mM) for 2 h and then stimulated with LPS (10
ng/ml) for 24 h. Caspase-1 activity was determined by a colorimetric
kit using substrates (A). Caspase-1 was determined by western blot
analysis (B). Data shown are the inhibition rate ± S.D. for 10 donors,
measured in duplicate. *P < 0.05, significantly different from the
unstimulated cells. **P < 0.05 compared to LPS alone. Quer,
quercetin.
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Page 8 of 11endogenous pyrogen, an activating factor of lymphocyte
products, and is made in many cells, especially in
macrophages. It activates T-cells and B-cells, causing an
inflammatory response [34]. IL-6 is a pleiotropic inflam-
matory cytokine produced by T-cells, monocytes, and
macrophages [35]. TNF-a itself promotes inflammation,
leukocyte infiltration, granuloma formation and tissue
fibrosis and is thought to be an initiator of cytokine-
related inflammatory states by stimulating cytokine pro-
duction in other types of cells [36]. Elevated levels of
circulating IL-1b,I L - 6 ,I L - 8 ,a n dT N F - a have been
reported previously in association with various patholo-
gical states including sepsis, rheumatoid arthritis,
osteoarthritis, asthma, and CI [1,2,37-39]. In our study,
CYT and quercetin inhibited IL-1b,I L - 6 ,a n dT N F - a
production and expression. Therefore, we suggest that
CYT and quercetin inhibit inflammatory reaction by
preventing the expression of inflammation-related genes.
Further investigation is necessary to more precisely clar-
ify the regulatory mechanisms of CYT involved in pre-
venting LPS-induced inflammatory cytokine expression.
Activation of the NF-B transcription family plays an
important role in inflammation because it induces tran-
scription of proinflammatory genes [40]. This pathway is
activated via cellular stimulation, most often from sig-
nals related to pathogens or stress. New therapeutic
interventions aimed at limiting the activation of NF-B
may have a beneficial effect in treating these pathologi-
cal states [41]. Previously, glucocorticoids, which are fre-
quently used in the treatment of inflammatory bowel
disease and rheumatoid arthritis, were suggested to sup-
press NF-B activation. Sulfasalazine and aucubin,
which are potent and specific inhibitors of NF-B, inhi-
bit activation without preventing AP-1 binding activity
[42,43]. Tang et al., reported that quercetin inhibits NF-
B activation in macrophages [44]. Our results suggest
that CYT and quercetin inhibit NF-B activation by
stopping IBa degradation. As such, CYT may modulate
inflammation due to infection by preventing NF-B acti-
vation in PBMCs.
IL-32 activates both the NF-Ba n dp 3 8M A P Kp a t h -
ways, which induce the gene transcription of proinflam-
matory cytokines, and it also activates proinflammatory
caspases, such as caspase-1 [14]. IL-32-induced prosta-
glandin E2 release is important in inflammatory
responses by both mouse macrophages and human blood
monocytes. Following injection of human IL-32g into
knee joints of naïve mice, joint swelling with pronounced
influx of inflammatory cells and cartilage damage is
observed [45]. IL-32 acts in a synergistic manner with the
intracellular nuclear oligomerization domain (NOD)1-
and NOD2-specific muropeptides of peptidoglycans,
resulting in release of IL-1b and IL-6 [14]. The synergy
between IL-32 and synthetic muramyl dipeptide/NOD2
in releasing IL-6 is dependent on activation of caspase-1
and release of IL-1b [45]. Only the additive effects of IL-
32 and muropeptides were observed to cause TNF-a pro-
duction [45]. Production of IL-32 occurs in response to
influenza A virus infection via COX-2 in the inflamma-
tory cascade [46]. Caspase-1 is involved in inflammatory
responses by causing cytokine maturation [47]. In this
study, CYT and quercetin inhibited LPS-induced cas-
pase-1 activation and IL-32 production. Caspase-1 inhibi-
tor also prevented IL-32 production. Therefore, we
suggest that CYT inhibits IL-32 production by blocking
caspase-1 activation. We also found that caspase-1 and
IL-32 play an important role in activating NF-B.
Conclusion
In conclusion, we suggest that CYT and quercetin
decrease LPS-induced inflammatory cytokine production
by inhibiting NF-B and caspase-1 activation. CYT may
be useful in the treatment of inflammatory diseases.
However, its other components should be isolated and
examined in additional studies to clarify whether they
may also be effective in treating CI.
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